Thu, Nov 27, 2014, 12:47 AM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

Dendreon Corp. Message Board

dwcity98 6 posts  |  Last Activity: Nov 9, 2014 10:08 AM Member since: Jan 18, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The few that remain are life long investors who will never sell period. As for the institutional investors, they remain and appear to be adding shares. They do not need direct information because they have contacts and resources that give them the Intel needed to know what is going on at Dendreon, institutions can contact large Provenge providers for updates on demand, or currier services on bookings, or monitor the processing plants parking lots for activity. Bottom line, institutions know what is going on and from the SEC filings, institutions are not selling, but accumulating.

  • Reply to

    More amazing data on the effectiveness of Procenge

    by dwcity98 Sep 28, 2014 10:16 AM
    dwcity98 dwcity98 Sep 28, 2014 5:01 PM Flag

    Thanks for posting the complete report Havenger.
    The statistical difference between the control arm and the Provenge treated arm is positively stunning. It was reported as 79% in the Provenge arm verses 15% for the control arm. The Provenge arm showed more than a 4 fold increase at the tumor sight.
    As we learn how to sequence Provenge, " the results keep on getting better and better. "
    Hold on tight.

    Sentiment: Strong Buy

  • From the IV Board by Harry, and noted here by Havenger. This is major positive data with a p value less than .01. The Procenge treated group had an increase of 79% while the control group was at 15%. A 4 fold+ increase in the Provenge treatment group.. Looks to be a tremendous success.
    From this report:
    "...Increased infiltration of CD3+ T cells was evident at the tumor interface (mean = 6.39 x 10–3/μm2, 95% confidence interval [CI] = 5.20 to 7.58 x 10–3/μm2
    ) compared with the pretreatment biopsy (mean = 2.33 x 10–3/μm2
    , 95% CI = 1.66 to 2.99 x 10–3/μm2, P

    Sentiment: Strong Buy

  • dwcity98 dwcity98 Sep 14, 2014 6:46 AM Flag

    AGREE, DNDN holds tremendous value for a large pharma that has the worldwide resources to fully develop the platform. As time goes forward, the effective of Provenge increases.

    Dendreon holds tremendous value.

    Sentiment: Strong Buy

  • If you search the archives of the NYT you can find an article by Altman & Miller regarding a new experimental treatment for Ebola. The article does state that DNDN hold a patent for the process.
    Emory University is in Atlanta where the two Ebola patients were treated and cured. Dndn has a major processing plant in Atlanta. The process appeared to involve spiking the immune system to attack the Ebola viral antigen. Isn't this what DNDN Provenge does ?
    It does look like Dendreon is involved with the treatment for Ebola. I do not expect to hear anything from DNDN Investor Relations on this matter,
    Connect the dots, this could get hot........................

    Sentiment: Strong Buy

  • Reply to

    Vanguard, Blackrock, State Street, Primecap

    by whatsgoingon55 Sep 1, 2014 7:14 PM
    dwcity98 dwcity98 Sep 1, 2014 7:53 PM Flag

    Agree, if it was going bk they would of sold their position and would be long gone. By purchasing more shares they are anticipating a nice rebound in the share price. DNDN management may not give us minor shareholders the time of day, but I believe they provide plenty of info to the big boys and that is why they are buying and holding the stock. Good news is coming.

    Sentiment: Strong Buy

DNDN
0.1270.000(0.00%)Nov 18 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.